Rocket Pharmaceuticals, Inc. (RCKT)
NASDAQ: RCKT · Real-Time Price · USD
3.550
-0.030 (-0.84%)
At close: Jan 29, 2026, 4:00 PM EST
3.570
+0.020 (0.56%)
After-hours: Jan 29, 2026, 5:15 PM EST
Rocket Pharmaceuticals Employees
Rocket Pharmaceuticals had 299 employees as of December 31, 2024. The number of employees increased by 31 or 11.57% compared to the previous year.
Employees
299
Change (1Y)
31
Growth (1Y)
11.57%
Revenue / Employee
n/a
Profits / Employee
-$805,726
Market Cap
384.19M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 299 | 31 | 11.57% |
| Dec 31, 2023 | 268 | 28 | 11.67% |
| Dec 31, 2022 | 240 | 89 | 58.94% |
| Dec 31, 2021 | 151 | 60 | 65.93% |
| Dec 31, 2020 | 91 | 34 | 59.65% |
| Sep 30, 2020 | 84 | 35 | 71.43% |
| Jun 30, 2020 | 79 | 38 | 92.68% |
| Mar 31, 2020 | 72 | 32 | 80.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Autolus Therapeutics | 650 |
| Entrada Therapeutics | 183 |
| Enanta Pharmaceuticals | 120 |
| Neumora Therapeutics | 95 |
| Lineage Cell Therapeutics | 77 |
| Aclaris Therapeutics | 64 |
| PepGen | 57 |
| Tectonic Therapeutic | 51 |
RCKT News
- 15 days ago - Rocket Pharmaceuticals, Inc. (RCKT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 24 days ago - Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 4 weeks ago - Rocket Pharmaceuticals: Deep Dislocation Offers Asymmetric Upside On LAD-I Approval And Amended Danon Program - Seeking Alpha
- 2 months ago - Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference - Business Wire
- 3 months ago - Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress - Business Wire
- 3 months ago - FDA Acceptance Of Rocket Pharmaceuticals' Lead Gene Therapy Application Reestablishes Momentum For Stock - Benzinga
- 3 months ago - Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I) - Business Wire
- 3 months ago - Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire